| abstract |
The invention describes monoclonal antibodies recognizing the fourth domain of the vascular cell adhesion molecule immunoglobulin 1 (VCAM1). Said antibodies are effective, for example, in the treatment of acute inflammations and diseases characterized by adhesion of leukocytes caused by VCAM1, as well as in purification or diagnostic methods and in diagnostic kits, particularly when the distinction between the sixth domain and seventh domain forms of VCAM1 have an advantage. |